Sánchez-Guiu Isabel, Antón Ana I, Padilla José, Velasco Francisco, Lucia José F, Lozano Miguel, Cid Ana Rosa, Sevivas Teresa, Lopez-Fernandez María F, Vicente Vicente, González-Manchón Consuelo, Rivera José, Lozano María L
Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, Murcia, 30003, Spain.
Servicio de Hematología y Hemoterapia, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario, Córdoba, Spain.
Orphanet J Rare Dis. 2014 Dec 24;9:213. doi: 10.1186/s13023-014-0213-6.
The diagnostic evaluation of inherited platelet disorders (IPDs) is complicated and time-consuming, resulting in a relevant number of undiagnosed and incorrectly classified patients. In order to evaluate the spectrum of IPDs in individuals with clinical suspicion of these disorders, and to provide a diagnostic tool to centers not having access to specific platelets studies, we established the project "Functional and Molecular Characterization of Patients with Inherited Platelet Disorders" under the scientific sponsorship of the Spanish Society of Thrombosis and Haemostasis.
PATIENTS/METHODS: Subjects were patients from a prospective cohort of individuals referred for clinical suspicion of IPDs as well as healthy controls. Functional studies included light transmission aggregation, flow cytometry, and when indicated, Western-blot analysis of platelet glycoproteins, and clot retraction analysis. Genetic analysis was mainly performed by sequencing of coding regions and proximal regulatory regions of the genes of interest.
Of the 70 cases referred for study, we functionally and molecularly characterized 12 patients with Glanzmann Thrombasthenia, 8 patients with Bernard Soulier syndrome, and 8 with other forms of IPDs. Twelve novel mutations were identified among these patients. The systematic study of patients revealed that almost one-third of patients had been previously misdiagnosed.
Our study provides a global picture of the current limitations and access to the diagnosis of IPDs, identifies and confirms new genetic variants that cause these disorders, and emphasizes the need of creating reference centers that can help health care providers in the recognition of these defects.
遗传性血小板疾病(IPD)的诊断评估复杂且耗时,导致相当数量的患者未得到诊断或分类错误。为了评估临床怀疑患有这些疾病的个体中IPD的范围,并为无法进行特定血小板研究的中心提供诊断工具,我们在西班牙血栓与止血学会的科学赞助下开展了“遗传性血小板疾病患者的功能和分子特征”项目。
患者/方法:研究对象包括因临床怀疑患有IPD而被转诊的前瞻性队列中的患者以及健康对照。功能研究包括光透射聚集试验、流式细胞术,必要时还包括血小板糖蛋白的蛋白质印迹分析和血块收缩分析。基因分析主要通过对感兴趣基因的编码区和近端调控区进行测序来进行。
在转诊进行研究的70例病例中,我们对12例Glanzmann血小板无力症患者、8例Bernard Soulier综合征患者和8例其他形式的IPD患者进行了功能和分子特征分析。在这些患者中鉴定出12个新的突变。对患者的系统研究表明,近三分之一的患者此前被误诊。
我们的研究全面呈现了当前IPD诊断的局限性和途径,识别并确认了导致这些疾病的新基因变异,并强调需要建立参考中心,以帮助医疗服务提供者识别这些缺陷。